Skip to Content
Merck

G117

Glipizide

solid

Synonym(s):

1-Cyclohexyl-3-{4-[2-(5-methylpyrazine-2-carboxamido)ethyl]phenylsulfonyl}urea

Sign In to View Organizational & Contract Pricing.

Select a Size

500 MG

MXP 2,987.00

1 G

MXP 4,181.00

MXP 2,987.00


Check Cart for Availability

Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):
C21H27N5O4S
CAS Number:
Molecular Weight:
445.54
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
249-427-6
MDL number:

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Glipizide, solid

InChI key

ZJJXGWJIGJFDTL-UHFFFAOYSA-N

InChI

1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)

SMILES string

Cc1cnc(cn1)C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3

form

solid

color

white

solubility

methanol: 1.9 mg/mL
DMSO: 48 mg/mL

Quality Level

Gene Information

Looking for similar products? Visit Product Comparison Guide

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
PHR1818G03400001292507
form

solid

form

powder

form

-

form

-

Quality Level

100

Quality Level

300

Quality Level

-

Quality Level

-

solubility

methanol: 1.9 mg/mL, DMSO: 48 mg/mL

solubility

-

solubility

-

solubility

-

color

white

color

-

color

-

color

-

Gene Information

human ... ABCC8(6833), KCNJ1(3758), KCNJ11(3767)

Gene Information

human ... ABCC8(6833), KCNJ11(3767)

Gene Information

human ... ABCC8(6833), KCNJ11(3767)

Gene Information

human ... ABCC8(6833), KCNJ11(3767)

Application

Glipizide has been used in:
  • chick embryo yolk sac membrane (YSM) and chorioallantoic membrane (CAM) assay[1]
  • MCF-7 breast cancer assay on chorioallantoic membrane (CAM)[1]
  • metastasis assays[1][2]
  • rat aortic ring assay[2]
  • in vivo matrigel plug assay
  • 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay[2]
  • flow cytometry[2]
  • western blotting[2]

Biochem/physiol Actions

Potassium inwardly-rectifying channel, subfamily J, member 1 (KCNJ1) plays a vital role in potassium balance.[3] It is an ATP-dependent K+ channel blocker. The encoded protein is liable for the elimination of potassium in exchange for the absorption of sodium by the epithelial sodium channel (ENaC).[4] Mutation in KCNJ1 is linked with several diseases, such as, antenatal Bartter syndrome and diabetes.[3] Glipizide helps to repress the development of tumors and metastasis by preventing angiogenesis.[1]

General description

Potassium inwardly-rectifying channel, subfamily J, member 1 (KCNJ1) codes for a renal outer medullary potassium channel (ROMK1, Kir1.1).[4] Glipizide is an antidiabetic drug, that is used to treat type II diabetes.(5)

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

KCNJ1 inhibits tumor proliferation and metastasis and is a prognostic factor in clear cell renal cell carcinoma
Guo Z, et al.
Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine, 36(2), 1251-1259 (2015)
Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment
Karnes JH, et al.
The Pharmacogenomics Journal, 13(5), 430-430 (2013)
Glipizide suppresses prostate cancer progression in the TRAMP model by inhibiting angiogenesis
Qi C, et al.
Scientific reports, 6(20), 27819-27819 (2016)
K M Pantalone et al.
Diabetes, obesity & metabolism, 14(9), 803-809 (2012-04-11)
It remains uncertain if differences in mortality risk exist among the sulfonylureas, especially in patients with documented coronary artery disease (CAD). The purpose of this study was to assess the overall mortality risk of the individual sulfonylureas versus metformin in
Korbinian Löbmann et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 81(1), 159-169 (2012-02-23)
The objective of this study was to prepare a co-amorphous drug/drug combination between two BCS class II drugs, simvastatin (SVS) and glipizide (GPZ). This pharmacologically relevant combination of two drugs could produce a promising candidate for formulations intended for combination

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service